Clinical trial
Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult…
NCT00007423 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00007423 |
|---|---|
| Title | Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in Uganda |
| Official title | A Phase I Study of the Safety and Immunogenicity of Live Recombinant ALVAC-HIV vCP205 in HIV-1 Uninfected Adult Volunteers in Uganda |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Joint Clinical Research Center MRC/UVRI and LSHTM Uganda Research Unit Joint UN Programme on HIV/AIDS (UNAIDS) Fogarty International Center of the National Institute of Health NIH Case Western Reserve… |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Biological |
| Interventions | ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65) |
| Enrollment | 40 |
| Completion | Sep 1, 2001 |
| First posted | Aug 31, 2001 |
| Last update posted | Nov 1, 2021 |
| Countries | Uganda |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: